The FDA’s fast-tracking of two molecularly targeted cancer drugs signals a major shift in medicine — and the cancer therapy marketplace.

Today, Pfizer and Roche have an edge with their newly approved drugs. But analysts say the flexibility of smaller companies could ultimately give them the edge in new market niches where therapies no longer focus on where the cancer is located, but the cells’ molecular make up and the patient’s genetic factors.

Whether this shift represents a concern or an opportunity depends on how you navigate the next five years. Here’s how to see what’s coming — today.

OrderToday

In one research-packed source, Targeted Cancer Drugs: The Launch Landscape to 2018 delivers the data and analysis you need to evaluate established approaches vs. emerging therapies, understand the competitive environment and turn trend forecasts into a head start for success.

Look inside 79 pipeline cancer drugs and the companies developing them. For each of these upcoming cancer treatment products, you’ll know: the mode of action, clinical data, and development risks. You’ll also know when each product is expected to launch and how it will compete with existing cancer drugs.

Buy now to get the information you need to strengthen your position as the cancer therapy market changes dramatically during the next five years, including:

• What the current R&D environment looks like for cancer therapies
• Which molecular targets industry is most interested in pursuing
• Which new products focus on treating lung, breast and colorectal cancer
• Therapeutic details, competitive impact and launch timelines for 79 products expected to hit the market by 2018
• How the competitive landscape will change over the next five years
• Which development pathways have the greatest potential for success — and which companies are pursuing them
• Emerging opportunities for smaller companies — including which companies have already established development/marketing collaborations

The comprehensive research and analysis in Targeted Cancer Drugs has been gathered for you by Sue Viney, a senior oncology analyst for Espicom Business Intelligence, a firm that has covered global healthcare markets for more than 30 years.

Whether you want marketwide perspective or details on a specific company niche or cancer therapy product, Targeted Cancer Drugs delivers the data, analysis and forecasts you need to move forward quickly — and with confidence.

Buy Now
Targeted Cancer Drugs: The Launch Landscape to 2018 is offered by FDAnews in print or PDF format for $2,265.

Satisfaction Guaranteed
There's no risk when you purchase from FDAnews with our money-back guarantee. Not satisfied with your publication? Return the hard copy within 30 days (in resalable condition), and we will refund 100 percent of your purchase price (less shipping/handling). For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase to receive a refund.